Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol

British Journal of Clinical Pharmacology

Volumn 58, Issue 1, 2004, Pages 81-87

  Hennessy, Sean ^a,b   Bilker, Warren B ^a   Knauss, Jill S ^a   Kimmel, Stephen E ^a,b   Margolis, David J ^a,b   Morrison, Mary F ^b,c   Reynolds, Robert F ^c,d   Glasser, Dale B ^d   Strom, Brian L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PFIZER INC   (United States)

Author keywords

Antipsychotic agents; Arrhythmia; Cohort studies; Pharmacoepidemiology

Indexed keywords

HALOPERIDOL; THIORIDAZINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CALCULATION; COMPARATIVE STUDY; DATA ANALYSIS; DATA BASE; DOSE RESPONSE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUDDEN DEATH; UNITED KINGDOM; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CHILD; COHORT ANALYSIS; HEART ARRHYTHMIA; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; PROGNOSIS; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; THIORIDAZINE;

EID: 4844231757     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02098.x     Document Type: Article

References (23)

1. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002; 54: 188-202.
2. Sides GD. QT interval prolongation as a biomarker for torsades de pointes and sudden death in drug development. Dis Markers 2002; 18: 57-62.
3. Al Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003; 289: 2120-7.
4. Briefing document for Zeldox capsules, submitted by Pfizer Inc. to the US Food Drug Administration, 2000; http://www.fda.gov/ohrms/dockets/ac/00/backgrd/ 3619bla.pdf accessed 25 May 2003
5. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 1997; 157: 2013-5.
6. Kemper AJ, Dunlap R, Pietro DA. Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol. JAMA 1983; 249: 2931-4.
7. Strom BL. Study designs available for pharmacoepidemiology studies. In Pharmacoepidemiology, ed. Strom BL. Chichester, UK: John Wiley and Sons, Inc., 2000.
8. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psych 2001; 58: 1161-7.
9. Hennessy S, Bilker WB, Knauss JS et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. Br Med J 2002; 325: 1070.
10. Carson JL, Strom BL. Medicaid databases. In Pharmacoepidemiology, ed. Strom BL. Chichester, UK: John Wiley & Sons Inc., 2000.
11. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-25.
12. de Abajo FJ, Rodriguez LA. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br J Clin Pharmacol 1999; 47: 307-13.
13. Walker AM, Szneke P, Weatherby LB et al. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada. Am J Med 1999; 107: 356-62.
14. Smith P. United Kingdom death certificates: a resource for geneologists and historians, 2002; 12-4. http://www.paul_smith.doctors.org.uk/ UKDeathCertificates.htm
15. Messite J, Stellman SD. Accuracy of death certificate completion: the need for formalized physician training. JAMA 1996; 275: 794-6.
16. Thomas BM, Starr JM, Whalley LJ. Death certification in treated cases of presenile Alzheimer's disease and vascular dementia in Scotland. Age Ageing 1997; 26: 401-6.
17. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B) 1972; 34: 187-220.
18. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-36.
19. Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system. Br Med J 1993; 307: 32-4.
20. Baldessarini RJ, Katz B, Cotton P. Dissimilar dosing with high-potency and low-potency neuroleptics. Am J Psychiatry 1984; 141: 748-52.
21. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989-1998. Circulation 2001; 104: 2158-63.
22. Lerena A, de la Berecz RRA, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16: 361-4.
23. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-52.